Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.76 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.69 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.69 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.69 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.69 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 0.69 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 0.69 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.63 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | ACACB | O00763 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12017852 | 0.87 | SIGMAR1 (0.74) | SIGMAR1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL1175467 | 0.87 | SIGMAR1 (0.74) | SIGMAR1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL4270067 | 0.87 | SIGMAR1 (1.00) | SIGMAR1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL8185938 | 0.86 | SIGMAR1 (0.84) | SIGMAR1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL11176916 | 0.83 | DRD2 (0.62) | SIGMAR1HDAC8HDAC6HDAC3HDAC4 | |
| Hydrochloric Acid SCHEMBL10503101 | 0.82 | DRD2 (0.61) | SIGMAR1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL1176274 | 0.81 | HDAC3 (0.83) | SIGMAR1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL1176271 | 0.81 | HDAC3 (0.83) | SIGMAR1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL863907 | 0.81 | SIGMAR1 (0.59) | SIGMAR1HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL8565758 | 0.80 | SIGMAR1 (0.63) | SIGMAR1HDAC8HDAC6HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062322-A1 | Novel Tricyclic Spiropiperidines or Spiropyrrolidines | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062322-A1 | Novel Tricyclic Spiropiperidines or Spiropyrrolidines | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062322-A1 | Novel Tricyclic Spiropiperidines or Spiropyrrolidines | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-7449475-B2 | Tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2008-11-11 | — | — | US | disclosed |
| US-7449475-B2 | Tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2008-11-11 | — | — | US | disclosed |
| US-7449475-B2 | Tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2008-11-11 | — | — | US | disclosed |
| EP-1521757-B1 | TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2008-01-30 | — | — | EP | disclosed |
| EP-1521757-B1 | TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2008-01-30 | — | — | EP | disclosed |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| US-6936600-B2 | Sorbitol dehrydrogenase inhibitors | PFIZER INC (US) | 2005-08-30 | — | — | US | disclosed |
| US-6869943-B2 | Sorbitol dehydrogenase inhibitors | PFIZER INC (US) | 2005-03-22 | — | — | US | disclosed |
| US-20050020578-A1 | Sorbitol dehydrogenase inhibitors | PFIZER INC. | 2005-01-27 | — | — | US | disclosed |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2004-04-22 | — | — | US | disclosed |
| WO-2004005295-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
| US-6660740-B1 | Sorbitol dehydrogenase inhibitors | PFIZER INC | 2003-12-09 | — | — | US | disclosed |
| US-6602875-B2 | Sorbitol dehydrogenase inhibitors | PFIZER INC | 2003-08-05 | — | — | US | disclosed |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2003-04-03 | — | — | US | disclosed |
| US-6414149-B1 | TREATING DIABETES, TREATING OR PREVENTING DIABETIC COMPLICATIONS | PFIZER INC. | 2002-07-02 | — | — | US | disclosed |
| EP-1185275-A1 | AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000059510-A1 | AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062322-A1 | Novel Tricyclic Spiropiperidines or Spiropyrrolidines | REN, TACR1, AGTR1 | SIGMAR1 238/4885HDAC8 1629/4885HDAC6 697/4885 |
| US-20050020578-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | SIGMAR1 2062/4885HDAC8 2683/4885HDAC6 1448/4885 |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | REN, TACR1, AGTR1 | SIGMAR1 194/4885HDAC8 1569/4885HDAC6 690/4885 |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | SIGMAR1 2002/4885HDAC8 2707/4885HDAC6 1545/4885 |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | SIGMAR1 2002/4885HDAC8 2707/4885HDAC6 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.